Access the full text.
Sign up today, get DeepDyve free for 14 days.
(2013)
Effect of the angiotensin II receptor antagonist olmesartan on morning home blood pressure in hypertension: HONEST study at 16 weeksJ Hum Hypertens, 27
N. Hollenberg (2004)
Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension.Current hypertension reports, 6 2
E. O'Brien, G. Parati, G. Stergiou, R. Asmar, L. Beilin, G. Bilo, D. Clement, A. Sierra, P. Leeuw, E. Dolan, R. Fagard, John Graves, G. Head, Y. Imai, K. Kario, E. Lurbe, J. Mallion, G. Mancia, T. Mengden, M. Myers, G. Ogedegbe, T. Ohkubo, Stefano Omboni, P. Palatini, J. Redón, L. Ruilope, A. Shennan, J. Staessen, G. vanMontfrans, P. Verdecchia, B. Waeber, Jiguang Wang, A. Zanchetti, Yuqing Zhang (2013)
European Society of Hypertension position paper on ambulatory blood pressure monitoring.Journal of hypertension, 31 9
(2011)
Management of hypertension in patients with diabetes using an amlodipine-, olmesartan medoxomil-, and hydrochlorothiazide-based titration regimenAm J Cardiol, 107
(Tofé Povedano, García de la Villa B. 24-hour and night-time blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J Clin Hypertens (Greenwich). 2009;11:473–9.)
Tofé Povedano, García de la Villa B. 24-hour and night-time blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J Clin Hypertens (Greenwich). 2009;11:473–9.Tofé Povedano, García de la Villa B. 24-hour and night-time blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J Clin Hypertens (Greenwich). 2009;11:473–9., Tofé Povedano, García de la Villa B. 24-hour and night-time blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. J Clin Hypertens (Greenwich). 2009;11:473–9.
Brian Rayner (2007)
Combination therapy in hypertensionSouth African Family Practice, 49
(Parati G, Stergiou GS, Asmar R, et al. On behalf of the ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens. 2008;26:1505–26.)
Parati G, Stergiou GS, Asmar R, et al. On behalf of the ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens. 2008;26:1505–26.Parati G, Stergiou GS, Asmar R, et al. On behalf of the ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens. 2008;26:1505–26., Parati G, Stergiou GS, Asmar R, et al. On behalf of the ESH Working Group on Blood Pressure Monitoring. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens. 2008;26:1505–26.
(Clement DL, de Buyzere ML, de Bacquer DA, et al. Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407–15.)
Clement DL, de Buyzere ML, de Bacquer DA, et al. Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407–15.Clement DL, de Buyzere ML, de Bacquer DA, et al. Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407–15., Clement DL, de Buyzere ML, de Bacquer DA, et al. Office versus Ambulatory Pressure Study Investigators. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003;348:2407–15.
(Tóth K, for the PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14:137–45 (Erratum in Am J Cardiovasc Drugs. 2014;14:239).)
Tóth K, for the PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14:137–45 (Erratum in Am J Cardiovasc Drugs. 2014;14:239).Tóth K, for the PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14:137–45 (Erratum in Am J Cardiovasc Drugs. 2014;14:239)., Tóth K, for the PIANIST Investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients). Am J Cardiovasc Drugs. 2014;14:137–45 (Erratum in Am J Cardiovasc Drugs. 2014;14:239).
(2013)
Rationale, study design, baseline characteristics and blood pressure at 16 weeks in the HONEST StudyHypertens Res, 36
Tó th K, for the PIANIST Investigators
(Shimada K, Ogihara T, Saruta T, Kuramoto K, for the REZALT Study Group. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study. Clin Ther. 2010;32:861–81.)
Shimada K, Ogihara T, Saruta T, Kuramoto K, for the REZALT Study Group. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study. Clin Ther. 2010;32:861–81.Shimada K, Ogihara T, Saruta T, Kuramoto K, for the REZALT Study Group. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study. Clin Ther. 2010;32:861–81., Shimada K, Ogihara T, Saruta T, Kuramoto K, for the REZALT Study Group. Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study. Clin Ther. 2010;32:861–81.
(2013)
Assessment and management of blood-pressure variabilityNat Rev Cardiol., 10
(2011)
24-hour efficacy and safety of Triple-Combination Therapy With Olmesartan, Amlodipine, and Hydrochlorothiazide: the TRINITY ambulatory blood pressure substudyJ Clin Hypertens (Greenwich)., 13
(2010)
Influence of circadian time of hypertension treatment on cardiovascular risk: result of the MAPEC studyChronobiol Int, 27
(2004)
Cardiovascular prognosis of ‘masked hypertension’ detected by blood pressure self-measurement in elderly treated hypertensive patientsJAMA, 291
(2010)
Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) studyTher Adv Cardiovasc Dis., 4
(2005)
Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome studyHypertension, 46
(2010)
Home blood pressure as a cardiovascular outcome predictor: it’s time to take this method seriouslyHypertension, 55
K. Shimada, T. Ogihara, T. Saruta, K. Kuramoto (2010)
Effects of combination olmesartan medoxomil plus azelnidipine versus monotherapy with either agent on 24-hour ambulatory blood pressure and pulse rate in Japanese patients with essential hypertension: additional results from the REZALT study.Clinical therapeutics, 32 5
(2011)
A titrate-to-goal study of switching patients uncontrolled on antihypertensive monotherapy to fixed-dose combinations of amlodipine and olmesartan medoxomil ± hydrochlorothiazideJ Clin Hypertens (Greenwich)., 13
(2012)
On behalf of the CARDIORISC Event Investigators. Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry: the CARDIORISC Event studyJ Hypertens, 30
(2007)
International Database on Ambulatory blood pressure monitoring in relation to Cardiovascular Outcomes (IDACO) Investigators. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort studyLancet, 370
(2005)
Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama studyHypertension, 45
(2012)
Combined effect of angiotensin II receptor blocker and either a calcium channel blocker or diuretic on day-by-day variability of home blood pressure: the Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy StudyHypertension, 59
K. Tóth, O. investigators (2014)
Erratum to: Antihypertensive Efficacy of Triple Combination Perindopril/Indapamide Plus Amlodipine in High-Risk Hypertensives: Results of the PIANIST Study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients)American Journal of Cardiovascular Drugs, 14
Yukinao Sakai, Anna Suzuki, K. Mugishima, Yuichiro Sumi, Yusuke Otsuka, Tomoyuki Otsuka, Dai Ohno, T. Murasawa, S. Tsuruoka (2013)
Comparison of once daily versus twice daily olmesartan in patients with chronic kidney diseaseInternational Journal of Nephrology and Renovascular Disease, 6
(2013)
COMPATIBLE Study Group. Comparison of effects of angiotensin II receptor blocker on morning home blood pressure and cardiorenal protection between morning administration and evening administration in hypertensive patients: the COMPATIBLE studyHypertens Res, 36
(Jiang H, Ke YN, Sun NL, Wang JG, Hou MW, Zhu JR, On behalf of Olmesartan Medoxomil Clinical Collaborative Panel of EXPO Study. Using different methods to evaluate the efficacy of olmesartan medoxomil in Chinese patients with mild to moderate essential hypertension according to ambulatory blood pressure monitoring. Blood Press Monit. 2012;17:193–7.)
Jiang H, Ke YN, Sun NL, Wang JG, Hou MW, Zhu JR, On behalf of Olmesartan Medoxomil Clinical Collaborative Panel of EXPO Study. Using different methods to evaluate the efficacy of olmesartan medoxomil in Chinese patients with mild to moderate essential hypertension according to ambulatory blood pressure monitoring. Blood Press Monit. 2012;17:193–7.Jiang H, Ke YN, Sun NL, Wang JG, Hou MW, Zhu JR, On behalf of Olmesartan Medoxomil Clinical Collaborative Panel of EXPO Study. Using different methods to evaluate the efficacy of olmesartan medoxomil in Chinese patients with mild to moderate essential hypertension according to ambulatory blood pressure monitoring. Blood Press Monit. 2012;17:193–7., Jiang H, Ke YN, Sun NL, Wang JG, Hou MW, Zhu JR, On behalf of Olmesartan Medoxomil Clinical Collaborative Panel of EXPO Study. Using different methods to evaluate the efficacy of olmesartan medoxomil in Chinese patients with mild to moderate essential hypertension according to ambulatory blood pressure monitoring. Blood Press Monit. 2012;17:193–7.
G. Parati, J. Ochoa, C. Lombardi, G. Bilo (2014)
Assessment and management of blood-pressure variabilityNature Reviews Cardiology, 11
P. Bramlage, Claudia Zemmrich, A. Gansz, C. Sturm, R. Fimmers, J. Nadal, R. Schmieder, J. Schrader, S. Lüders (2014)
Daytime Systolic Ambulatory Blood Pressure With a Two‐Step Switch From Candesartan to Olmesartan Monotherapy and the Fixed‐Dose Combination of Olmesartan/Amlodipine in Patients With Uncontrolled Essential Hypertension (SEVICONTROL‐2)The Journal of Clinical Hypertension, 16
Carlos Schettini, Manuel Bianchi, F. Nieto, E. Sandoya, H. Senra (1999)
Ambulatory Blood PressureHypertension, 34
(Bramlage P, Zemmrich C, Gansz A, et al. Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2). J Clin Hypertens (Greenwich). 2014;16:41–6.)
Bramlage P, Zemmrich C, Gansz A, et al. Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2). J Clin Hypertens (Greenwich). 2014;16:41–6.Bramlage P, Zemmrich C, Gansz A, et al. Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2). J Clin Hypertens (Greenwich). 2014;16:41–6., Bramlage P, Zemmrich C, Gansz A, et al. Daytime systolic ambulatory blood pressure with a two-step switch from candesartan to olmesartan monotherapy and the fixed-dose combination of olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-2). J Clin Hypertens (Greenwich). 2014;16:41–6.
(O’Brien E, Parati G, Stergiou G, et al, On behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731–68.)
O’Brien E, Parati G, Stergiou G, et al, On behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731–68.O’Brien E, Parati G, Stergiou G, et al, On behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731–68., O’Brien E, Parati G, Stergiou G, et al, On behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens. 2013;31:1731–68.
(2013)
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney diseaseHypertension, 61
(2011)
24-Hour ambulatory blood pressure control with triple-therapy amlodipine, valsartan and hydrochlorothiazide in patients with moderate to severe hypertensionJ Hum Hypertens, 25
M. Gorostidi, A. Sierra, O. González-Albarrán, J. Segura, J. Cruz, E. Vinyoles, J. Llisterri, P. Aranda, L. Ruilope, J. Banegas (2011)
Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetesHypertension Research, 34
W. Elliott (2008)
Prognostic accuracy of day versus night ambulatory blood pressure: a cohort studyYearbook of Cardiology, 2008
(2011)
How to best assess blood pressure? The ongoing debate on the clinical value of blood pressure average and variabilityHypertension, 57
(1998)
Home blood pressure measurement has a stronger predictive power for mortality than screening blood pressure measurement: a population-based observation in OhasamaJapan J Hypertens., 16
(Gorostidi M, de la Sierra A, González-Albarrán O, et al. On behalf of the Spanish Society of Hypertension ABPM Registry investigators. Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes. Hypertens Res. 2011;34:1185–9.)
Gorostidi M, de la Sierra A, González-Albarrán O, et al. On behalf of the Spanish Society of Hypertension ABPM Registry investigators. Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes. Hypertens Res. 2011;34:1185–9.Gorostidi M, de la Sierra A, González-Albarrán O, et al. On behalf of the Spanish Society of Hypertension ABPM Registry investigators. Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes. Hypertens Res. 2011;34:1185–9., Gorostidi M, de la Sierra A, González-Albarrán O, et al. On behalf of the Spanish Society of Hypertension ABPM Registry investigators. Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes. Hypertens Res. 2011;34:1185–9.
K. Tóth, O. investigators (2014)
Antihypertensive Efficacy of Triple Combination Perindopril/Indapamide Plus Amlodipine in High-Risk Hypertensives: Results of the PIANIST Study (Perindopril-Indapamide plus AmlodipiNe in high rISk hyperTensive patients)American Journal of Cardiovascular Drugs, 14
(Jiao Y, Ke Y, Sun N, Wang J, Deng W, Zhu J, on behalf of the Olmesartan Medoxomil Clinical Collaborative Panel of the EXPO Study. Reduction of the morning blood pressure surge treated with olmesartan in Chinese patients with mild to moderate essential hypertension-a multicenter, open-label, single treatment group clinical study. Eur Rev Med Pharmacol Sci. 2012;16:653–9.)
Jiao Y, Ke Y, Sun N, Wang J, Deng W, Zhu J, on behalf of the Olmesartan Medoxomil Clinical Collaborative Panel of the EXPO Study. Reduction of the morning blood pressure surge treated with olmesartan in Chinese patients with mild to moderate essential hypertension-a multicenter, open-label, single treatment group clinical study. Eur Rev Med Pharmacol Sci. 2012;16:653–9.Jiao Y, Ke Y, Sun N, Wang J, Deng W, Zhu J, on behalf of the Olmesartan Medoxomil Clinical Collaborative Panel of the EXPO Study. Reduction of the morning blood pressure surge treated with olmesartan in Chinese patients with mild to moderate essential hypertension-a multicenter, open-label, single treatment group clinical study. Eur Rev Med Pharmacol Sci. 2012;16:653–9., Jiao Y, Ke Y, Sun N, Wang J, Deng W, Zhu J, on behalf of the Olmesartan Medoxomil Clinical Collaborative Panel of the EXPO Study. Reduction of the morning blood pressure surge treated with olmesartan in Chinese patients with mild to moderate essential hypertension-a multicenter, open-label, single treatment group clinical study. Eur Rev Med Pharmacol Sci. 2012;16:653–9.
(2013)
Combination therapy in hypertensionAdv Ther., 30
(2013)
Enhanced blood pressure-lowering effect of olmesartan in hypertensive patients with chronic kidney disease-associated sympathetic hyperactivity: HONEST StudyJ Clin Hypertens (Greenwich)., 15
Y. Jiao, Y. Ke, N. Sun, Ji-Guang Wang, W. Deng, Jun-ren Zhu (2012)
Reduction of the morning blood pressure surge treated with olmesartan in Chinese patients with mild to moderate essential hypertension--a multicenter, open-label, single treatment group clinical study.European review for medical and pharmacological sciences, 16 5
(1994)
Ambulatory blood pressure. An independent predictor of prognosis in essential hypertensionHypertension, 24
(2012)
Achievement of cardiometabolic goals in aware hypertensive patients in Spain: a nationwide population-based studyHypertension, 60
Santiago Povedano, B. Villa (2009)
24‐Hour and Nighttime Blood Pressures in Type 2 Diabetic Hypertensive Patients Following Morning or Evening Administration of OlmesartanThe Journal of Clinical Hypertension, 11
M. Kikuya, T. Ohkubo, K. Asayama, H. Metoki, T. Obara, Shin Saito, J. Hashimoto, K. Totsune, H. Hoshi, H. Satoh, Y. Imai (2005)
, Mortality : The Ohasama Study Ambulatory Blood Pressure and 10-Year Risk of Cardiovascular and Noncardiovascular
(2014)
2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)JAMA, 311
(2013)
2013 ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)J Hypertens, 31
M. Gorostidi, P. Sarafidis, A. Sierra, J. Segura, J. Cruz, J. Banegas, L. Ruilope (2013)
Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: A 5,693-patient cross-sectional analysis from Spain.American journal of kidney diseases : the official journal of the National Kidney Foundation, 62 2
M. Gorostidi, J. Sobrino, J. Segura, C. Sierra, A. Sierra, R. Rey, E. Vinyoles, J. Galcerán, M. LÓPEZ-EADY, R. Marín, J. Banegas, A. Sarría, A. Coca, L. Ruilope (2007)
Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20 000-patient database in SpainJournal of Hypertension, 25
(Gorostidi M, Sobrino J, Segura J, et al. On behalf of the Spanish Society of Hypertension ABPM Registry investigators. Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20,000-patient database in Spain. J Hypertens. 2007;25:977–84.)
Gorostidi M, Sobrino J, Segura J, et al. On behalf of the Spanish Society of Hypertension ABPM Registry investigators. Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20,000-patient database in Spain. J Hypertens. 2007;25:977–84.Gorostidi M, Sobrino J, Segura J, et al. On behalf of the Spanish Society of Hypertension ABPM Registry investigators. Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20,000-patient database in Spain. J Hypertens. 2007;25:977–84., Gorostidi M, Sobrino J, Segura J, et al. On behalf of the Spanish Society of Hypertension ABPM Registry investigators. Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20,000-patient database in Spain. J Hypertens. 2007;25:977–84.
(2009)
On behalf of the Spanish Society of Hypertension Ambulatory Blood Monitoring Registry Investigators. Prevalence and factors associated with circadian blood pressure patterns in hypertensive patientsHypertension, 53
(2007)
IDACO Investigators. Prognostic superiority of daytime ambulatory over conventional blood pressure in four populations: a meta-analysis of 7,030 individualsJ Hypertens, 25
(2014)
Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysisEur Heart J, 35
(2014)
Efficacy of olmesartan/amlodipine combination therapy in reducing ambulatory blood pressure in moderate-to-severe hypertensive patients not controlled by amlodipine aloneHypertens Res, 37
G. Mancia, R. Fagard, K. Narkiewicz, Josep Redán, A. Zanchetti, Michael Böhm, T. Christiaens, R. Cífková, G. Backer, A. Dominiczak, M. Galderisi, D. Grobbee, Tiny Jaarsma, Paulus Kirchof, S. Kjeldsen, S. Laurent, A. Manolis, P. Nilsson, L. Ruilope, R. Schmieder, P. Sirnes, Peter Sleight, Margus Viigimaa, Bernard Waeber, F. Zannad (2013)
2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension.Journal of hypertension, 31 10
Hong Jiang, Y. Ke, N. Sun, Ji-Guang Wang, Mingru Hou, Jun-ren Zhu (2012)
Using different methods to evaluate the efficacy of olmesartan medoxomil in Chinese patients with mild to moderate essential hypertension according to ambulatory blood pressure monitoringBlood Pressure Monitoring, 17
(National Institute for Health and Clinical Excellence (NICE). Hypertension. The clinical management of primary hypertension in adults. Clinical Guideline 127. 2011. Available at: www.nice.org.uk/guidance/CG127. Accessed 11 June 2015.)
National Institute for Health and Clinical Excellence (NICE). Hypertension. The clinical management of primary hypertension in adults. Clinical Guideline 127. 2011. Available at: www.nice.org.uk/guidance/CG127. Accessed 11 June 2015.National Institute for Health and Clinical Excellence (NICE). Hypertension. The clinical management of primary hypertension in adults. Clinical Guideline 127. 2011. Available at: www.nice.org.uk/guidance/CG127. Accessed 11 June 2015., National Institute for Health and Clinical Excellence (NICE). Hypertension. The clinical management of primary hypertension in adults. Clinical Guideline 127. 2011. Available at: www.nice.org.uk/guidance/CG127. Accessed 11 June 2015.
(2014)
Clinical practice guidelines for the management of hypertension in the community a statement by the American Society of Hypertension and the International Society of HypertensionJ Hypertens, 32
(2014)
Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trialsJ Hypertens, 32
(2012)
Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studiesJ Hypertens, 30
(2008)
Call to action on use and reimbursement for home blood pressure monitoring: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses AssociationHypertension, 52
(2010)
Home-measured blood pressure is a stronger predictor of cardiovascular risk than office blood pressure: the Finn-Home studyHypertension, 55
(2013)
Daytime systolic ambulatory blood pressure with a direct switch between candesartan monotherapy and the fixed-dose combination olmesartan/amlodipine in patients with uncontrolled essential hypertension (SEVICONTROL-1)J Clin Hypertens (Greenwich)., 15
(Sakai Y, Suzuki A, Mugishima K, et al. Comparison of once daily versus twice daily olmesartan in patients with chronic kidney disease. Int J Nephrol Renovasc Dis. 2013:11(6):223–7.)
Sakai Y, Suzuki A, Mugishima K, et al. Comparison of once daily versus twice daily olmesartan in patients with chronic kidney disease. Int J Nephrol Renovasc Dis. 2013:11(6):223–7.Sakai Y, Suzuki A, Mugishima K, et al. Comparison of once daily versus twice daily olmesartan in patients with chronic kidney disease. Int J Nephrol Renovasc Dis. 2013:11(6):223–7., Sakai Y, Suzuki A, Mugishima K, et al. Comparison of once daily versus twice daily olmesartan in patients with chronic kidney disease. Int J Nephrol Renovasc Dis. 2013:11(6):223–7.
(1999)
Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension. Systolic Hypertension in Europe Trial InvestigatorsJAMA, 282
(2013)
The effects of telmisartan alone or with hydrochlorothiazide on morning and 24-h ambulatory BP control: results from a practice-based study (SURGE 2)Hypertens Res, 36
G. Mancia, R. Fagard, K. Narkiewicz, J. Redón, A. Zanchetti, M. Böhm, T. Christiaens, R. Cífková, G. Backer, A. Dominiczak, M. Galderisi, D. Grobbee, T. Jaarsma, P. Kirchhof, S. Kjeldsen, S. Laurent, A. Manolis, P. Nilsson, L. Ruilope, R. Schmieder, P. Sirnes, P. Sleight, M. Viigimaa, B. Waeber, F. Zannad (2007)
2013 ESH/ESC Guidelines for the management of arterial hypertensionBlood Pressure, 22
(Gorostidi M, Sarafidis PA, de la Sierra A, et al. On behalf of the Spanish ABPM Registry. Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: A 5,693-patient cross-sectional analysis from Spain. Am J Kidney Dis. 2013;62:285–94.)
Gorostidi M, Sarafidis PA, de la Sierra A, et al. On behalf of the Spanish ABPM Registry. Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: A 5,693-patient cross-sectional analysis from Spain. Am J Kidney Dis. 2013;62:285–94.Gorostidi M, Sarafidis PA, de la Sierra A, et al. On behalf of the Spanish ABPM Registry. Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: A 5,693-patient cross-sectional analysis from Spain. Am J Kidney Dis. 2013;62:285–94., Gorostidi M, Sarafidis PA, de la Sierra A, et al. On behalf of the Spanish ABPM Registry. Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: A 5,693-patient cross-sectional analysis from Spain. Am J Kidney Dis. 2013;62:285–94.
T. Pickering, N. Miller, G. Ogedegbe, L. Krakoff, N. Artinian, D. Goff (2008)
Call to Action on Use and Reimbursement for Home Blood Pressure Monitoring: A Joint Scientific Statement From the American Heart Association, American Society of Hypertension, and Preventive Cardiovascular Nurses AssociationThe Journal of Cardiovascular Nursing, 23
(2005)
Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) studyCirculation, 111
(2007)
Comparison of the efficacy of morning versus evening administration of olmesartan in uncomplicated essential hypertensionChromobiol Int., 24
(2009)
A randomized, double blind, four-arm parallel-group study of the efficacy and safety of azelnidipine and olmesartan medoxomil combination therapy compared with each monotherapy in Japanese patients with essential hypertension: the REZALT studyHypertens Res, 32
G. Parati, G. Stergiou, R. Asmar, G. Bilo, P. Leeuw, Y. Imai, K. Kario, E. Lurbe, A. Manolis, T. Mengden, E. O'Brien, T. Ohkubo, P. Padfield, P. Palatini, T. Pickering, J. Redón, M. Revera, L. Ruilope, A. Shennan, J. Staessen, A. Tislér, B. Waeber, A. Zanchetti, G. Mancia (2008)
European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure MonitoringJournal of Hypertension, 26
Ambulatory blood pressure (BP) correlates more significantly with hypertension-associated cardiovascular mortality and morbidity than BP obtained in the doctor’s office. Assessing ambulatory BP, either through 24-h monitoring or through protocolized self-measurement at home, is essential in diagnosing and monitoring patients with hypertension. Several ambulatory BP-derived indicators are related with cardiovascular prognosis. These include 24-h, daytime and nighttime BP measurements, BP measurements obtained through home self-measurement, dipping status, morning surge, and BP variability. The objective of this article was to review the effect of olmesartan-based antihypertensive therapy on the main risk variables obtained when assessing ambulatory BP.
Cardiology and Therapy – Springer Journals
Published: Jun 13, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.